Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 56 Breast Neoplasms 7 Bulbo-Spinal Atrophy, X-Linked 4 Neoplasms 3 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Salivary Gland Neoplasms 2 Stage I Prostate Adenocarcinoma 1 Recurrence 1 Paget Disease, Extramammary 1 PSA Level Greater Than Two 1 Ovarian Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Lower Urinary Tract Symptoms 1 Gynecomastia 1 Fallopian Tube Neoplasms 1 Erectile Dysfunction 1 Carcinoma, Transitional Cell 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms, Male 1 Adenocarcinoma 1

Interventions

pembrolizumab 31 Gemcitabine 26 Nivolumab 20 atezolizumab 16 Cisplatin 15 avelumab 14 Carboplatin 12 Docetaxel 10 enfortumab vedotin 8 Magnetic Resonance Spectroscopy 8 durvalumab 7 Specimen Handling 7 Paclitaxel 7 Ipilimumab 6 toripalimab 5 pemigatinib 5 cabozantinib 5 vinflunine 4 sacituzumab govitecan 4 Taxes 4 Pemetrexed 4 tislelizumab 3 cabazitaxel 3 Standard of Care 3 Mitomycin 3 Injections 3 Everolimus 3 Albumin-Bound Paclitaxel 3 sapanisertib 2 olaparib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Transitional Cell × bicalutamide × Clear all

NCT06018116 2024-02-15

CANUCK-01

CHU de Quebec-Universite Laval

Phase 2 Withdrawn

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡